Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARASTEP darolutamide plus ADT in high-risk biochemical recurrence of prostate cancer
2022-501343-33-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT with Placebo + ADT (2 arms). Primary endpoint: rPFS by PSMA PET/CT assessed by BICR. Planned start Jul 2023; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-501343-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501343-33-00.